PO.BCS01.06 · 生物信息与计算
人工智能从H&E切片衍生的空间转录组学特征可预测原发性黑色素瘤的生存
Artificial intelligence derived spatial transcriptomic signatures from H&E slides predict survival in primary melanoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:黑色素瘤表现出显著的空间和分子异质性,这驱动肿瘤进展和临床结局。虽然空间转录组学(ST)检测能够捕获这种复杂性,但其高成本和有限的组织可用性阻碍了广泛应用。计算病理学的最新进展使得能够直接从常规苏木精-伊红(H&E)全切片图像(WSI)预测空间基因表达,为真正的空间分析提供了一种可扩展的虚拟替代方案。本工作探究从TCGA-SKCM H&E切片提取的人工智能(AI)衍生ST特征能否作为原发性黑色素瘤总生存期(OS)的预后生物标志物。
方法:我们分析了来自TCGA-SKCM且具有可用生存数据的原发性黑色素瘤福尔马林固定石蜡包埋H&E WSI(N=292名患者)。数据集按30:70的比例随机分割,生成训练队列(N=87)和测试队列(N=205)。WSI被分割为290x290像素的图块,并使用预训练的DeepSpot模型预测5000个基因的空间表达。下游分析限于从既往文献中筛选出的18个黑色素瘤相关基因。这些基因的AI预测空间基因表达值被汇总为每点和每基因描述符,产生269个定量特征,涵盖统计指标、空间自相关指数和Ripley's K衍生的空间聚集测度。在去除高度相关和低方差特征后,使用自助法LASSO回归选择前5个生存信息性特征。使用Cox比例风险模型创建一个整合的AI特征。10年OS的模型性能采用风险比(HR)、一致性指数、对数秩检验以及在训练和留出测试队列上的Kaplan Meier分析进行评估。
结果:生存时间在10年处右删失,产生116例观察到的死亡和176例删失患者。AI衍生的ST特征由KRT6B、UBE2L6和PFKFB3基因的空间特征以及平均基因表达组成,并显著地按OS对患者进行分层。在训练集中,高风险组的生存显著较差(HR=3.39;95% CI:1.67-6.88;p<0.001,C-index=0.654)。在测试队列中的独立验证证实了预后效用(HR=2.17;95% CI:1.37-3.44;p=0.001;C-index=0.615),证明了泛化性。
结论:从标准H&E切片衍生的AI推断ST特征捕获了与原发性黑色素瘤结局相关的具有生物学意义的模式。这一虚拟组学流程为预后判断提供了一种可扩展且非破坏性的方法,并可能在ST不可行的环境中补充或替代传统的分子检测。
查看英文原文 English abstract
Introduction: Melanoma exhibits pronounced spatial and molecular heterogeneity, which drives tumor progression and clinical outcomes. While spatial transcriptomics (ST) assays can capture this complexity, their high cost and limited tissue availability hinder widespread use. Recent advances in computational pathology enable prediction of spatial gene expression directly from routine Hematoxylin and Eosin (H&E) whole slide images (WSIs), providing a scalable virtual alternative for true spatial profiling. This work investigates whether artificial intelligence (AI) derived ST features extracted from TCGA-SKCM H&E slides can serve as prognostic biomarkers of overall survival (OS) in primary melanoma.
Methods: We analyzed formalin-fixed paraffin-embedded H&E WSI of primary melanoma from TCGA-SKCM with available survival data (N=292 patients). Dataset was randomly split in a 30:70 ratio to generate training (N=87) and testing (N=205) cohorts. WSI were divided into patches of 290x290 pixels, and spatial expression of 5000 genes was predicted using the pretrained DeepSpot model. Downstream analyses were limited to 18 melanoma-relevant genes shortlisted from prior literature. AI predicted spatial gene expression values of these genes were summarized into per-spot and per-gene descriptors, producing 269 quantitative features encompassing statistical metrics, spatial autocorrelation indices, and Ripley's K derived spatial clustering measures. After removing highly correlated and low-variance features, bootstrapped LASSO regression was used to select the top 5 survival-informative features. A Cox proportional hazards model was used to create an integrated AI signature. Model performance for 10-year OS was evaluated using hazard ratios (HR), concordance indices, log-rank tests, and Kaplan Meier analyses on training and holdout testing cohorts.
Results: Survival times were right-censored at 10 years, resulting in 116 observed deaths and 176 censored patients. AI derived ST signature consisted of spatial features for KRT6B, UBE2L6, and PFKFB3 genes, along with average gene expression, and significantly stratified patients by OS. In the training set, the high-risk group had significantly poorer survival (HR = 3.39; 95% CI: 1.67-6.88; p < 0.001, C-index = 0.654). Independent validation in the testing cohort confirmed prognostic utility (HR = 2.17; 95% CI: 1.37-3.44; p = 0.001; C-index = 0.615), demonstrating generalizability.
Conclusion: AI inferred ST features derived from standard H&E slides capture biologically meaningful patterns associated with outcomes in primary melanoma. This virtual-omics pipeline provides a scalable and non-destructive approach for prognostication and may complement or substitute traditional molecular assays in settings where ST is not feasible.
利益披露 Disclosure
A. Singh, None..
M. George, None..
T. Pathak, None..
U. Baid, None..
D. Parker, None..
M. C. Lowe, None.
A. Madabhushi,
Picture Health g., Board of Directors, non-salaried role), Stock, Other Intellectual Property.
Elucid Bioimaging Stock, Other Intellectual Property.
Inspirata Inc. Other Business Ownership, ).
Takeda Inc. Independent Contractor.
AstraZeneca ).
Bristol Myers Squibb ).
B. Baheti, None.